GILD - Gilead Sciences, Inc.
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the company, MarketBeat reports....
Csenge Advisory Group raised its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 319.0% in the undefined quarter, according to the company in its most recent filing with the Securities and...
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8...
Conning Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 8.5% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 291,475 shares of the...
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.
Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June...
Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry conference that kicked off on Monday...
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Daniel O'Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV...
If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Childress Capital Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 68.5% during the undefined quarter, according to the company in its most recent Form 13F filing with...
DALLAS--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”) today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (“Gilead”) to evaluate OncoNano's ON-BOARD™...
Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.
Railway Pension Investments Ltd increased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 3.1% in the undefined quarter, according to its most recent disclosure with the Securities and...
CWA Asset Management Group LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 16.6% during the undefined quarter, according to the company in its most recent 13F filing with the...
Brookwood Investment Group LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the third quarter, according to its most recent filing with the Securities and Exchange...
Of the host of financial metrics investors might consider when deciding whether to buy shares of a target company, cash flow is among the most important. Operating cash flow is a reflection of how...
Bank Pictet and Cie Europe AG lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 502.8% during the undefined quarter, according to its most recent disclosure with the Securities...